PRESS RELEASE published on 01/31/2024 at 17:03, 2 years 8 months ago EQS-Adhoc: Vita 34 publishes preliminary figures on the course of business in 2023 Vita 34 AG publishes preliminary figures on the course of business in 2023, reporting Group revenue of EUR 76.8 million and preliminary EBITDA of EUR 4.0 million, which fell short of expectations due to extraordinary charges. The company plans to invest in cell and gene therapies and CDMO following the merger with PBKM EBITDA 2023 Vita 34 AG Preliminary Figures Cell And Gene Therapies
PRESS RELEASE published on 11/10/2023 at 14:57, 2 years 11 months ago EQS-Adhoc: Internal investigation by Vita 34 AG reveals irregularities related to a limited number of biological samples at one of its subsidiaries regarding compliance with medical law requirements
PRESS RELEASE published on 09/27/2023 at 19:21, 3 years ago EQS-Adhoc: Vita 34 AG: A subsidiary of Vita 34, FamiCordTx, will file a lawsuit against a US licensor
PRESS RELEASE published on 08/31/2023 at 10:30, 3 years 1 month ago Vita 34 stabilizes business development in the second quarter and noticeably improves earnings
PRESS RELEASE published on 05/31/2023 at 08:00, 3 years 4 months ago Vita 34 successfully implements price increases in first quarter of 2023 in generally weak market environment
PRESS RELEASE published on 05/12/2023 at 09:10, 3 years 5 months ago Vita 34 Starts Recruitment for Clinical Trial with CAR-T Drug Candidate
PRESS RELEASE published on 04/30/2023 at 12:00, 3 years 5 months ago Development of Vita 34 AG in 2022 stressed by weakened consumption power of consumers along with one-off effects
PRESS RELEASE published on 04/25/2023 at 18:43, 3 years 5 months ago EQS-Adhoc: Vita 34 AG publishes outlook for the 2023 financial year
PRESS RELEASE published on 04/06/2023 at 20:39, 3 years 6 months ago EQS-Adhoc: 2022 annual result of Vita 34 AG significantly influenced by impairment of goodwill
Published on 10/24/2026 at 00:04, 1 day 9 hours ago Sparta Capital Ltd. Provides Corporate Update on Reinstatement Review, Financial Statement Corrections and Governance Matters
Published on 10/23/2026 at 23:30, 1 day 9 hours ago Algo Grande Commissions Independent NI 43-101 Update to Capture First Year of Progress at Adelita
Published on 10/23/2026 at 21:55, 1 day 11 hours ago Apex Closes Offering and Completes NASDAQ Listing
Published on 10/23/2026 at 16:00, 1 day 17 hours ago Leggett Dynamics's Mid-Class Massage System Wins Gasgoo's Best Technical Practice Award
Published on 10/24/2026 at 23:44, 10 hours 43 minutes ago EQS-Adhoc: HomeToGo SE: Unauthorized data exfiltration at subsidiary SECRA Bookings GmbH
Published on 10/24/2026 at 14:15, 20 hours 13 minutes ago Winners of the 2026 INPD Awards Announced, C-Beauty Takes Home Multiple Prestigious Honors
Published on 10/24/2026 at 06:30, 1 day 2 hours ago AI and EV Boom Draws $690 Million in Advanced Materials Investment Plans to Thailand
Published on 10/23/2026 at 18:55, 1 day 14 hours ago Qatar's Years of Culture Initiative Announces Partner Countries Through 2030
Published on 10/23/2026 at 18:00, 1 day 15 hours ago BIOSYNEX SA: CHEMBIO DIAGNOSTIC SYSTEMS AWARDED $5.7 MILLION TO ADVANCE DPP® BIOTHREAT PANEL
Published on 10/23/2026 at 20:33, 1 day 12 hours ago Disclosure of transactions in own shares from October 19 to October 23, 2026
Published on 10/23/2026 at 17:45, 1 day 15 hours ago Imerys-10-2026-information-share-capital-and-voting-rights-as-of-30-September-2026
Published on 10/22/2026 at 18:00, 2 days 15 hours ago THERMADOR GROUPE : Completion of the share buy-back programme launched in August
Published on 10/22/2026 at 18:00, 2 days 15 hours ago bioMérieux receives Dual 510(k) Clearance and CLIA Waiver from the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel to Advance Women’s Health with Rapid Molecular Diagnostics
